Financials
Financial year 2025
TotalPharma from Antwerpen, company number BE0797048802, closed financial year 2025 with a result of € 76,362 after tax. For that financial year TotalPharma recorded a gross margin of € 143,476 and equity of € 246,119. Compared with financial year 2024, the result moved from € 56,701 to € 76,362. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 21, 2026.
€ 246,119
▲ 45% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 76,362
▲ 35% vs 2024
Profit after tax over the fiscal year.
€ 154,713
▲ 143% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 243,119.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 10,266
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 33,547
Of which on lease € 33,547.
Debts at end 2025
€ 32,550
€ 7,636 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 28,309
▲ 70% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 39,477
▼ 24% vs 2024
Taxes, VAT and social contributions still to pay.
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 206,591 | € 102,713 | € 143,476 | ▲ 40% |
| Profit after taxes | € 110,056 | € 56,701 | € 76,362 | ▲ 35% |
| Equity | € 113,056 | € 169,758 | € 246,119 | ▲ 45% |
| Total debts | € 105,237 | € 68,539 | € 100,336 | ▲ 46% |
| Cash | € 52,664 | € 63,549 | € 154,713 | ▲ 143% |
| Retained profit | € 110,056 | € 166,758 | € 243,119 | ▲ 46% |
| Bank debt | € 0 | € 0 | € 32,550 | |
| Balance sheet total | € 218,293 | € 238,296 | € 346,455 | ▲ 45% |
Key figures of TotalPharma, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to TotalPharma?
What happened at TotalPharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 76,362 (▲ 35% vs 2024). filed late Source: NBB ↗
- New establishment in Antwerpen. KBO
- Steven Verbeeck became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 110,056 profit in 2023 to € 76,362 profit in 2025.
Paid € 72,132 in corporate taxes since 2023.
Best year ever: 2023, with € 110,056 profit.
Management
Behind TotalPharma is Steven Verbeeck. Steven Verbeeck is also behind Netcomm.
Directors
According to the 2025 annual accounts
since 2023
Establishments
Establishment units
Physical locations of this company
Brusselstraat 51
2018 Antwerpen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
A2HOSTING - A2 Hosting, Inc., US
Website info
Features
Security
Details
- Company number
- 0797.048.802
- VAT number
- BE 0797.048.802
- Registered office
- Brusselstraat 51, 2018 Antwerpen
- Names & denominations
- TotalPharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 11 January 2023
- Peppol
- Active · Active since 18 Dec 2025
- Contact
- techpharma.be
- Activities · NACE
Ontwerpen van computerprogramma’s
Ontwerpen en programmeren van computerprogramma's
Activiteiten op het gebied van computerconsultancy en beheer van computerfaciliteiten
Computerconsultancy-activiteiten